* Clene Inc. reported a quarterly adjusted loss of $1.22 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of six analysts for the quarter was for a loss of $1.32 per share. Wall Street expected results to range from $-1.51 to $-1.09 per share.
* Revenue fell 19.4% to $87.00 thousand from a year ago; analysts expected $90.00 thousand.
* Clene Inc.'s reported EPS for the quarter was a loss of $1.22.
* The company reported a quarterly loss of $7.99 million.
* Clene Inc. shares had risen by 15.5% this quarter and lost 10.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 0.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Clene Inc. is 30.50 This summary was machine generated from LSEG data November 13 at 02:14 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.32 -1.22 Beat
Jun. 30 2024 -1.49 -1.06 Beat
Mar. 31 2024 -1.60 -1.80 Missed
Dec. 31 2023 -1.45 -1.20 Beat
Comments